CUROVERSE, INC.

BOSTON, MA · Founded 2010 · CIK 0001586571 · Biotech · Acquired

Arvados, a computational platform for managing, processing, and analyzing massive genomic datasets in real time

curoverse.com →
Grants
$1.6M
2 awards
Sector median: 1
Raised
$2.0M
2 Form D · Mar 2015
139 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,499,999
Private capital raisedForm D · SEC$500,000
Federal grantDepartment of Health and Human Services · Phase I · An Open Source Precision Medicine Platform for Cloud Operating Systems$149,947
Federal grantDepartment of Health and Human Services · Phase II · An Open Source Precision Medicine Platform for Cloud Operating Systems$1,500,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2552Regenimo Biosciences, Inc.—$2.0M
2553Venn Therapeutics, LLC——
2554Kovina Therapeutics Inc.—$2.0M
2555CUROVERSE, INC.—$2.0M
2556NEXILICO, INC.——
2557Hennepin Life Sciences—$1.9M
2558Biomakers, Inc.—$1.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Jeremy AllaireDirector
  • Adam BerreyDirector · Executive Officer
  • Michael DialDirector
  • David MartiranoDirector
  • Clay ThropDirector
  • Ward VandewegeExecutive Officer
  • Alexander Wait ZaranekDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.